Literature DB >> 230930

Distinction between benign and malignant type of Parkinson's disease.

W Birkmayer, P Riederer, B H Youdim.   

Abstract

Clinical data demonstrate that there is a significant difference between at least two types of idiopathic Parkinsonian patients; a benign type of Parkinson's disease and a malignant type. They can be distinguished by the time course of a disability-score, independent of the duration of the disease. The benign cases respond very well to L-Dopa (Madopar) treatment and show a long lasting (7 years) drop in the disability, whereas the improvement of disability in the malignant cases is much smaller and lasts for about one year, followed by an increase of disability. The duration of the disease is 12,5 +/- 0,4 years in the benign type but only 4,0 +/- 0,3 years in the malignant type. Akinetic crises, off-phases, hyperkinetic crises and toxic deliria after Madopar treatment can be observed later in the benign than in the malignant cases. These results suggest that the degeneration of the dopaminergic nigrostriatal system occurs much more rapidly in malignant cases than in benign cases of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 230930     DOI: 10.1016/0303-8467(79)90003-9

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  6 in total

1.  CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease.

Authors:  Peter LeWitt; Lonni Schultz; Peggy Auinger; Mei Lu
Journal:  Brain Res       Date:  2011-07-01       Impact factor: 3.252

Review 2.  Neuropsychological aspects of Parkinson's disease.

Authors:  S A Raskin; J C Borod; J Tweedy
Journal:  Neuropsychol Rev       Date:  1990-09       Impact factor: 7.444

3.  The effect of age of disease onset on neuropsychological performance in Parkinson's disease.

Authors:  M Hietanen; H Teräväinen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-02       Impact factor: 10.154

Review 4.  Is "Parkinson's disease" one disease?

Authors:  D B Calne
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

5.  Transitional states of central serotonin receptors in Parkinson's disease.

Authors:  E Kienzl; P Riederer; K Jellinger; W Wesemann
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

6.  The emerging postural instability phenotype in idiopathic Parkinson disease.

Authors:  Frank M Skidmore; William S Monroe; Christopher P Hurt; Anthony P Nicholas; Adam Gerstenecker; Thomas Anthony; Leon Jololian; Gary Cutter; Adil Bashir; Thomas Denny; David Standaert; Elizabeth A Disbrow
Journal:  NPJ Parkinsons Dis       Date:  2022-03-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.